
    
      The investigational product consists of a novel higher concentration (30mg/mL) furosemide
      formulation developed for subcutaneous administration and a novel patch pump placed on the
      abdominal skin. This trial will investigate the on body performance of novel patch pump
      delivering the novel formulation. Study parameters include pharmacokinetic measurements and
      diuretic response following subcutaneous administration of 80mg of furosemide solution in
      2.7mL in patients with heart failure (HF). Recruitment will be restricted to 1 site with a
      recruitment target of 20 patients. All trial related activities will be conducted in an
      inpatient environment.
    
  